JP6644006B2 - エノラーゼ１（ｅｎｏ１）組成物及びその使用 - Google Patents

エノラーゼ１（ｅｎｏ１）組成物及びその使用 Download PDF

Info

Publication number
JP6644006B2
JP6644006B2 JP2016563908A JP2016563908A JP6644006B2 JP 6644006 B2 JP6644006 B2 JP 6644006B2 JP 2016563908 A JP2016563908 A JP 2016563908A JP 2016563908 A JP2016563908 A JP 2016563908A JP 6644006 B2 JP6644006 B2 JP 6644006B2
Authority
JP
Japan
Prior art keywords
eno1
certain embodiments
subject
diabetes
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016563908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508000A5 (enExample
JP2017508000A (ja
Inventor
ナレイン，ニーブン，ラジン
サランガラヤン，ランガプラサド
ビシュヌダス，ヴィヴェック，ケー．
ゲスタ，ステファヌ
ジン，エンシュアン
Original Assignee
バーグ エルエルシー
バーグ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーグ エルエルシー, バーグ エルエルシー filed Critical バーグ エルエルシー
Publication of JP2017508000A publication Critical patent/JP2017508000A/ja
Publication of JP2017508000A5 publication Critical patent/JP2017508000A5/ja
Application granted granted Critical
Publication of JP6644006B2 publication Critical patent/JP6644006B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
JP2016563908A 2014-01-13 2015-01-13 エノラーゼ１（ｅｎｏ１）組成物及びその使用 Expired - Fee Related JP6644006B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201461926913P 2014-01-13 2014-01-13
US61/926,913 2014-01-13
US201462009783P 2014-06-09 2014-06-09
US62/009,783 2014-06-09
US201562100881P 2015-01-07 2015-01-07
US62/100,881 2015-01-07
PCT/US2015/011275 WO2015106295A2 (en) 2014-01-13 2015-01-13 Enolase 1 (eno1) compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2017508000A JP2017508000A (ja) 2017-03-23
JP2017508000A5 JP2017508000A5 (enExample) 2018-02-22
JP6644006B2 true JP6644006B2 (ja) 2020-02-12

Family

ID=53524434

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016563908A Expired - Fee Related JP6644006B2 (ja) 2014-01-13 2015-01-13 エノラーゼ１（ｅｎｏ１）組成物及びその使用
JP2016563909A Expired - Fee Related JP6629234B2 (ja) 2014-01-13 2015-01-13 エノラーゼ１（ｅｎｏ１）組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016563909A Expired - Fee Related JP6629234B2 (ja) 2014-01-13 2015-01-13 エノラーゼ１（ｅｎｏ１）組成物及びその使用

Country Status (14)

Country Link
US (4) US10188707B2 (enExample)
EP (2) EP3094341B1 (enExample)
JP (2) JP6644006B2 (enExample)
KR (1) KR20160106175A (enExample)
CN (3) CN112336851A (enExample)
AU (2) AU2015204452A1 (enExample)
BR (1) BR112016016153A2 (enExample)
CA (2) CA2936694A1 (enExample)
EA (1) EA201691420A1 (enExample)
HK (1) HK1231425A1 (enExample)
IL (1) IL246720A0 (enExample)
MX (1) MX2016009102A (enExample)
SG (1) SG11201605698XA (enExample)
WO (2) WO2015106295A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
WO2016210008A1 (en) * 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
US20200185063A1 (en) 2016-06-05 2020-06-11 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
CN107991493B (zh) * 2017-11-22 2020-03-31 中国医科大学附属第一医院 抗eno1自身抗体在对ait孕妇筛查和预测流产风险中的应用
CN112111462B (zh) * 2020-09-14 2022-08-23 兰州大学 烯醇化酶eno1单克隆抗体及其应用
US20250243294A1 (en) * 2021-11-26 2025-07-31 Hunilife Biotechnology, Inc Methods to regulate glycolysis via targeting extracellular alpha-enolase for treating human diseases
CN114533902A (zh) * 2022-02-28 2022-05-27 河南师范大学 一种过表达lrrc15基因的质粒载体及其制备方法和应用
CN115786317B (zh) * 2022-12-12 2026-03-20 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE244576T1 (de) 1992-09-25 2003-07-15 Neorx Corp Therapeutischer inhibitor der vaskulären glatten muskelzellen
CZ122697A3 (en) 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US20030044795A1 (en) 1996-09-06 2003-03-06 Inger Byrajalsen Biochemical markers of the human endometrium
US7078375B1 (en) * 1996-10-25 2006-07-18 Peter Mose Larsen Diabetes-mediating proteins and therapeutic uses thereof
US6329501B1 (en) 1997-05-29 2001-12-11 Auburn University Methods and compositions for targeting compounds to muscle
WO2001016323A2 (en) 1999-09-01 2001-03-08 Subsidiary N0.3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU771546B2 (en) 1999-09-01 2004-03-25 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU2470101A (en) 1999-10-25 2001-05-08 Affymetrix, Inc. Genetic sequences associated with neural cell proliferation and disease
JP2003522183A (ja) 2000-02-02 2003-07-22 トランジェーヌ、ソシエテ、アノニム ターゲッティングペプチド
US20030203372A1 (en) 2000-12-08 2003-10-30 Ward Neil Raymond Analysis method
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
US20040058326A1 (en) 2001-07-27 2004-03-25 Brooksbank Robert Alan Identification and use of molecules implicated in pain
US20050191627A1 (en) 2001-09-28 2005-09-01 Incyte Corporation Enzymes
WO2003064501A1 (en) 2002-01-31 2003-08-07 Clarke Slemon Conformationally restricted compounds as dendrimer cores
US20050222023A1 (en) 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
JP2004081111A (ja) 2002-08-27 2004-03-18 Yamaguchi Technology Licensing Organization Ltd 虚血性心疾患の治療薬として新規活性を有するα−エノラーゼおよびその利用法
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CN100446772C (zh) * 2002-12-06 2008-12-31 法布罗根股份有限公司 一种稳定HIFα的制剂在制备治疗糖尿病的药物中的应用
WO2004055519A2 (en) 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
WO2004061088A2 (en) 2002-12-30 2004-07-22 Ppd Development, Lp Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2004084950A2 (en) 2003-03-24 2004-10-07 Case Western Reserve University Cell targeting methods and compositions
US7473531B1 (en) 2003-08-08 2009-01-06 Colora Corporation Pancreatic cancer targets and uses thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005073621A (ja) 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
WO2005032572A2 (en) 2003-10-03 2005-04-14 Vib Vzw Means and methods for the recruitment and identification of stem cells
US8133733B2 (en) * 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
EP1664775A4 (en) 2004-07-06 2008-03-12 Kuhnil Pharm Co Ltd COMPOSITION FOR THE DIAGNOSIS OF RETINAL VASCULAR DISEASE COMPRISING ALDOLASE AND DIAGNOSTIC METHOD USING THE SAME
WO2007046818A2 (en) 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
US20080138913A1 (en) * 2005-01-03 2008-06-12 Sook-Yeong Jeon Composition for Prevention, Treatment, and Diagnosis of Chronic Inflammatory Airway Diseases
US7608413B1 (en) 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
JP5137814B2 (ja) 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
US20070248628A1 (en) 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
TWI304443B (en) 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
WO2008012362A2 (en) 2006-07-27 2008-01-31 Oxford Genome Sciences (Uk) Ltd New protein isoforms and uses thereof
KR20090094227A (ko) 2006-09-29 2009-09-04 리보박스 바이오테크놀로지즈 에스아 췌관 선암 관련 신규 항원 및 항체
US20100047256A1 (en) 2007-01-25 2010-02-25 Imperial Innovations Limited Methods
US20090110662A1 (en) 2007-04-30 2009-04-30 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
WO2009008727A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
JP5429707B2 (ja) 2008-03-27 2014-02-26 国立大学法人群馬大学 微粒子およびその製造方法
US20110130346A1 (en) 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
CN106173266A (zh) 2008-07-18 2016-12-07 希尔氏宠物营养品公司 治疗与体重过重动物相关的疾病的组合物和方法
EP2194382A1 (en) 2008-12-03 2010-06-09 Universität des Saarlandes An in-vitro method or assay for detecting a tumor or a cancerous disease by screening for antibodies
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
IT1398782B1 (it) 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
WO2011064552A1 (en) 2009-11-30 2011-06-03 Isis Innovation Limited Conjugates for delivery of biologically active compounds
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
WO2011147981A2 (en) 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
WO2012065034A1 (en) 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
ES2560012T3 (es) 2011-05-10 2016-02-17 Institut National De La Santé Et De La Recherche Médicale (Inserm) Métodos y composiciones farmacéuticas para el tratamiento de enfermedades autoinmunitarias
GB201113814D0 (en) 2011-08-10 2011-09-28 Proteome Sciences R & D Gmbh & Co Kg Materials and methods for determining sensitivity potential of compounds
WO2013030569A2 (en) 2011-08-30 2013-03-07 Michael John Gait Peptides
EP3603678A3 (en) 2011-12-14 2020-07-29 The Board of Regents of the University of Texas System Collateral gene inactivation biomarkers and targets for cancer therapy
EP2877214B1 (en) 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
CN111544601A (zh) 2012-10-30 2020-08-18 粒子科学有限公司 具有靶向部分的药物递送粒子制剂
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
WO2016210008A1 (en) 2015-06-22 2016-12-29 Berg Llc Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
WO2017011836A1 (en) 2015-07-16 2017-01-19 Berg Llc Enolase 1 (eno1) compositions and uses thereof

Also Published As

Publication number Publication date
WO2015106295A3 (en) 2015-11-05
HK1231394A1 (en) 2017-12-22
JP6629234B2 (ja) 2020-01-15
US10188707B2 (en) 2019-01-29
US10188708B2 (en) 2019-01-29
US20190307863A1 (en) 2019-10-10
AU2015204452A1 (en) 2016-08-11
WO2015106296A1 (en) 2015-07-16
WO2015106295A2 (en) 2015-07-16
EA201691420A1 (ru) 2016-12-30
US20150359861A1 (en) 2015-12-17
SG11201605698XA (en) 2016-08-30
US20150361409A1 (en) 2015-12-17
CN106102835A (zh) 2016-11-09
MX2016009102A (es) 2016-09-09
KR20160106175A (ko) 2016-09-09
EP3094341A1 (en) 2016-11-23
WO2015106296A8 (en) 2015-08-20
CA2936694A1 (en) 2015-07-16
EP3094379A2 (en) 2016-11-23
EP3094379A4 (en) 2017-06-28
US11224641B2 (en) 2022-01-18
IL246720A0 (en) 2016-08-31
CA2936691A1 (en) 2015-07-16
CN112336851A (zh) 2021-02-09
AU2015204451A1 (en) 2016-07-28
CN106659766A (zh) 2017-05-10
JP2017508000A (ja) 2017-03-23
EP3094341B1 (en) 2019-10-02
JP2017509690A (ja) 2017-04-06
BR112016016153A2 (pt) 2017-12-12
US20190307864A1 (en) 2019-10-10
CN106659766B (zh) 2025-03-28
EP3094341A4 (en) 2017-11-01
CN106102835B (zh) 2020-11-03
HK1231425A1 (zh) 2017-12-22

Similar Documents

Publication Publication Date Title
JP6629234B2 (ja) エノラーゼ１（ｅｎｏ１）組成物及びその使用
US20230078745A1 (en) Blood Biomarkers and Diagnostic Methods for Small Vessel Diseases
JPH09511492A (ja) アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
JPH07502534A (ja) インビボ進行グリコシル化最終産物の免疫化学的検出
AU2014366827A1 (en) Method of diagnosis and treatment
JP2019506374A (ja) メトホルミンのバイオマーカーとしての増殖分化因子１５
US20140186850A1 (en) Reagents and methods for bispecific antibody-based binding of target molecules
EP4051702B1 (en) Theranostics for hypertension induced myocardial microbleeds
US20160375113A1 (en) Compositions comprising eno1 and their use in methods of treating obesity or overweight and reducing weight gain
JP5739433B2 (ja) 血中インスリン抵抗性及び糖尿病マーカープログラニュリン、採血試料中のプログラニュリン濃度の分析方法、及び、インスリン抵抗性を改善及び糖尿病を改善又は抑制する物質のスクリーニング方法
HK1231394B (en) Enolase 1 (eno1) compositions and uses thereof
US20210063391A1 (en) Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device
MXPA99002313A (en) Materials and methods relating to the diagnosis and treatment of diabetes and obesity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180112

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20190416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200107

R150 Certificate of patent or registration of utility model

Ref document number: 6644006

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees